Research Ethics and Commercial Drug Development: When Integrity Threatens Profitability-Reference-Cited by-同舟云学术

Research Ethics and Commercial Drug Development: When Integrity Threatens Profitability

Published:2018-03-27 Issue: Volume:5 Page:
ISSN:1923-2799
Container-title:Case Study
language:
Short-container-title:bo

Author:

Bélisle Pipon Jean-Christophe¹²

Affiliation:

1. Bioethics Program, Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal, Québec, Canada

2. Institut de recherche en santé publique de l’Université de Montréal, Québec, Canada

Abstract

This case, based on personal experiences and on those found in the literature, highlights the delicate tension faced by drug development companies having to balance research integrity and their profitability.

Publisher

Consortium Erudit

Subject

Health Policy,Philosophy,Health (social science)

Reference17 articles.

1. 1MacDonald C. Business ethics 101 for the biotech industry. BioDrugs. 2004;18(2):71–7.

2. 2Fortin J-S, Bélisle Pipon J-C, Ganache I. Visées éthiques, développement et usage du médicament. In: Beaulieu P, Pichette V, Desroches J, du Souich P, editors. Précis de Pharmacologie. 2nd ed. Montréal, Québec: Presses de l’Université de Montréal; 2015. p. 1011–21.

3. 3Bélisle Pipon J-C, Williams-Jones B. Drug Familiarization and Therapeutic Misconception via Direct-To-Consumer Information. Journal of Bioethical Inquiry. 2015;12(2):259–67.

4. 4Bélisle Pipon J-C, Williams-Jones B. Regulating Direct-to-Consumer Drug Information: A Case Study of Eli Lilly’s Canadian 40over40 Erectile Dysfunction Campaign. Healthcare Policy Politiques de Santé. 2015;10(4):16–23.

5. 5Thakur P. Offshoring and outsourcing of core corporate activities: The global relocation of pharmaceutical industry clinical trials. [PhD]: Rutgers, The State University of New Jersey - Newark; 2010.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Améliorer la compréhension et la gestion des conflits d’intérêts des experts conseillant la prise de décisions en santé publique;Case Study;2018-03-27